Sansure Biotech Inc (688289) - Total Assets
Based on the latest financial reports, Sansure Biotech Inc (688289) holds total assets worth CN¥9.46 Billion CNY (≈ $1.38 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Sansure Biotech Inc's book value for net asset value and shareholders' equity analysis.
Sansure Biotech Inc - Total Assets Trend (2017–2024)
This chart illustrates how Sansure Biotech Inc's total assets have evolved over time, based on quarterly financial data.
Sansure Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Sansure Biotech Inc's total assets of CN¥9.46 Billion consist of 67.3% current assets and 32.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 53.4% |
| Accounts Receivable | CN¥588.27 Million | 6.8% |
| Inventory | CN¥392.75 Million | 4.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥429.36 Million | 5.0% |
| Goodwill | CN¥7.66 Million | 0.1% |
Asset Composition Trend (2017–2024)
This chart illustrates how Sansure Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sansure Biotech Inc (688289) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sansure Biotech Inc's current assets represent 67.3% of total assets in 2024, an increase from 56.3% in 2017.
- Cash Position: Cash and equivalents constituted 53.4% of total assets in 2024, up from 7.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 6.8% of total assets.
Sansure Biotech Inc Competitors by Total Assets
Key competitors of Sansure Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Teleflex Incorporated
NYSE:TFX
|
USA | $6.95 Billion |
|
Touchstone International Medical Science Co Ltd
SHG:688013
|
China | CN¥676.02 Million |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
Crossject
PA:ALCJ
|
France | €31.38 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Sansure Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.88 | 8.04 | 7.38 |
| Quick Ratio | 4.49 | 7.45 | 6.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.22 Billion | CN¥5.03 Billion | CN¥4.39 Billion |
Sansure Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Sansure Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.57 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | CN¥8.60 Billion |
| Market Capitalization | $1.46 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sansure Biotech Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sansure Biotech Inc's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sansure Biotech Inc (2017–2024)
The table below shows the annual total assets of Sansure Biotech Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.60 Billion ≈ $1.26 Billion |
+1.77% |
| 2023-12-31 | CN¥8.45 Billion ≈ $1.24 Billion |
-7.84% |
| 2022-12-31 | CN¥9.17 Billion ≈ $1.34 Billion |
+29.38% |
| 2021-12-31 | CN¥7.09 Billion ≈ $1.04 Billion |
+29.99% |
| 2020-12-31 | CN¥5.45 Billion ≈ $798.15 Million |
+748.98% |
| 2019-12-31 | CN¥642.47 Million ≈ $94.01 Million |
+16.38% |
| 2018-12-31 | CN¥552.04 Million ≈ $80.78 Million |
-2.40% |
| 2017-12-31 | CN¥565.61 Million ≈ $82.77 Million |
-- |
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more